Work

SHP2 Is a Target of the Immunosuppressant Tautomycetin

Year: 2011

Type: article

Source: Chemistry & Biology

DOI: 10.1016/j.chembiol.2010.10.015

Authors: Sijiu Liu, Zhihong Yu, Xiao Yu, Sheng-Xiong Huang, Yinggang Luo, Li Wu, Weihua Shen, Zhenyun Yang, Lina Wang, Andrea M. Gunawan, Rebecca J. Chan, Ben Shen, Zhong-Yin Zhang

Institutions: Indiana University Indianapolis, Indiana University School of Medicine, University of Wisconsin–Madison

Language: English

Topic: Protein Tyrosine Phosphatases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Chinese Academy of Sciences, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute

Awards: Activating PTPN11 and c-kit Mutations in Myeloproliferative Disorder, UWCCC National Cooperative Drug Discovery Group for Can*, Aberrant Monocytic Differentiation Induced by Gain-of-Function Shp2 Mutants, Small Molecule Inhibitors for the Oncogenic Protein Tyrosine Phosphatase SHP2, G2271657281, G3143017211, Targeting PRL Phosphatases for Cancer Therapy, G7541491422, G7564757906, G7800854979, G9000149842, Structure/Function of Protein Tyrosine Phosphatases, G90926137

OpenAlex ID: W2044513200

FWCI: 1.816

Cites: 50

Cited by: 44

Related to: 10